Omnicell is a health information services business based in the US. Omnicell shares (OMCL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $41.82 – a decrease of 10.26% over the previous week. Omnicell employs 3,660 staff and has a trailing 12-month revenue of around $1.1 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $41.82 |
|---|---|
| 52-week range | $25.12 - $55.75 |
| 50-day moving average | $44.19 |
| 200-day moving average | $34.18 |
| Wall St. target price | $56.14 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.39 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $42.41 from 2024-11-19
| 1 week (2024-11-14) | -8.99% |
|---|---|
| 1 month (2024-10-21) | 4.79% |
| 3 months (2024-08-21) | -2.46% |
| 6 months (2024-05-21) | 32.91% |
| 1 year (2023-11-21) | 30.61% |
|---|---|
| 2 years (2022-11-21) | -18.75% |
| 3 years (2021-11-19) | 183.23 |
| 5 years (2019-11-21) | 79.22 |
Valuing Omnicell stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omnicell's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Omnicell's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.28. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Omnicell's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Omnicell's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.5 million.
The EBITDA is a measure of a Omnicell's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.1 billion |
|---|---|
| Operating margin TTM | 2.54% |
| Gross profit TTM | $596.7 million |
| Return on assets TTM | -0.87% |
| Return on equity TTM | -1.46% |
| Profit margin | -1.66% |
| Book value | $26.59 |
| Market Capitalization | $2.2 billion |
TTM: trailing 12 months
We're not expecting Omnicell to pay a dividend over the next 12 months.
Over the last 12 months, Omnicell's shares have ranged in value from as little as $25.12 up to $55.745. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omnicell's is 0.815. This would suggest that Omnicell's shares are less volatile than average (for this exchange).
Omnicell, Inc. , together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.